What Tests Are Needed Before and During Tysabri Treatment?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one are considering Tysabri for multiple sclerosis, understanding the monitoring schedule is critical. The legacy of mass production in the health and science information domain has long emphasized broad public awareness of general wellness and disease prevention, which now extends to the specific safety protocols for this therapy. This page outlines the key tests and follow-up timeline recommended before and during treatment.

Medical Background and PML Risk

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Ohio who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is critical. PML is an opportunistic viral infection of the brain caused by the JC virus, which typically only occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, as stated in the drug's boxed warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive neurological deficits such as weakness, vision changes, speech difficulties, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid via PCR. The timeline between Tysabri exposure and documented harm varies; cases have been reported after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because PML often leads to irreversible disability or death, early recognition and cessation of Tysabri are critical.

Mechanistic Pathways and Adequacy of Warnings

The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri inhibits the migration of immune cells across the blood-brain barrier, reducing central nervous system immune surveillance. This immunosuppressive effect allows latent JC virus, which is present in many individuals, to reactivate and cause lytic infection of oligodendrocytes in the brain, leading to demyelination and the characteristic lesions of PML. The risk is amplified in patients with anti-JCV antibodies, as these indicate prior exposure to the virus. The prescribing information for Tysabri includes a boxed warning that clearly states the increased risk of PML and identifies the three major risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether the risks were adequately communicated to individual patients, particularly regarding the cumulative nature of risk over time and the need for regular monitoring.

Settlement-Related Considerations and Statute of Limitations in Ohio

For patients in Ohio who have developed PML after Tysabri treatment, legal claims may be pursued against the manufacturer, Biogen, for failure to warn or design defect. Settlement considerations often depend on the severity of injury, the presence of documented risk factors, and the timeline of exposure. Ohio's statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared. Given the progressive nature of PML, early legal consultation is advisable to preserve the right to seek compensation. The duration of Tysabri treatment prior to PML onset can range from a few months to several years, with risk increasing significantly after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This variable latency period complicates the determination of when the statute of limitations begins. Ohio courts typically apply the discovery rule, meaning the clock starts when the patient knew or should have known that Tysabri caused the injury. Medical records documenting the diagnosis and any prior discussions of risk are critical evidence.

Conclusion and Next Steps

Tysabri-associated PML is a devastating condition with well-defined risk factors and a clear mechanistic basis. While the drug's labeling includes prominent warnings, affected patients in Ohio must be aware of the statute of limitations for filing claims. Given the complexity of medical and legal issues, individuals who have developed PML after Tysabri treatment should seek prompt evaluation by both a neurologist and a legal professional experienced in pharmaceutical litigation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Ohio?

In Ohio, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared. It is crucial to consult an attorney promptly to preserve your rights.

What are the key risk factors for developing PML while on Tysabri?

The three key risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the drug's prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Tysabri Prescribing Information (DailyMed)

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.